[68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review

  • Am J Nucl Med Mol Imaging. 2020 Dec 15;10(6):349-374.
Frédéric Bois  1 ,  Camille Noirot  1 ,  Sébastien Dietemann  1 ,  Ismini C Mainta  1 ,  Thomas Zilli  2  3 ,  Valentina Garibotto  1  3 ,  Martin A Walter  1  3  4
Affiliations
  • 1. Division of Nuclear Medicine, Diagnostic Department, University Hospital of Geneva Geneva, Switzerland.
  • 2. Division of Radiation Oncology, Oncology Department, University Hospital of Geneva Geneva, Switzerland.
  • 3. Faculty of Medicine, University of Geneva Geneva, Switzerland.
  • 4. Center for Biomedical Imaging (CIBM) Lausanne, Switzerland.
PMID: 33329937
Abstract

Imaging of the prostate-specific membrane antigen (PSMA) has become an important tool for managing patients with recurrent prostate Cancer, and one of the most frequently employed radiopharmaceuticals is [68Ga]Ga-PSMA-11. Herein, we summarize the preclinical development and the clinical applications of [68Ga]Ga-PSMA-11 and present side-by-side comparisons with Other radiopharmaceuticals or imaging modalities, in order to assist imagers and clinicians in recommending, performing, and interpreting the results of [68Ga]Ga-PSMA-11 PET scans in patients with prostate Cancer.

Keywords
PSMA; Prostate cancer; molecular imaging; restaging; staging.
Products